Refine
Has Fulltext
- yes (30)
Is part of the Bibliography
- yes (30)
Document Type
- Journal article (29)
- Preprint (1)
Language
- English (30)
Keywords
- positron emission tomography (7)
- CXCR4 (6)
- PRRT (5)
- multiple myeloma (5)
- PET (4)
- PET/CT (4)
- lymphoma (4)
- FDG (3)
- chemokine receptor (3)
- medicine (3)
- molecular imaging (3)
- neuroendocrine tumor (3)
- theranostics (3)
- FDG-PET/CT (2)
- MAG3 (2)
- NET (2)
- PSMA (2)
- Positronen-Emissions-Tomografie (2)
- RADS (2)
- SSTR (2)
- SSTR-RADS (2)
- bone disease (2)
- in vivo imaging (2)
- involvement (2)
- peptide receptor radionuclide therapy (2)
- prostate cancer (2)
- 177Lu (1)
- 18-F-fluorothymidine uptake (1)
- 18FDG-PET/CT (1)
- 1st International Workshop (1)
- 5-Fluorouracil (1)
- 5IA-SPECT (1)
- 68Ga-DOTANOC (1)
- 68Ga-DOTATATE (1)
- 68Ga-DOTATOC (1)
- Arginine (1)
- B-cell lymphoma (1)
- BSS directive (1)
- CXCR4/SDF-1 (1)
- CYP11B enzymes (1)
- DLBCL (1)
- DNA repair (1)
- DOTATOC (1)
- FDG PET/CT (1)
- FDG-PET (1)
- FDG-PET/MRI (1)
- FLT-PET (1)
- Hodgkin-lymphoma (1)
- Hyperkalaemia (1)
- Lysine (1)
- MI-RADS (1)
- Merkel cell carcinoma (1)
- Molecular imaging (1)
- Multiple myeloma (1)
- NVP-BGT226 (1)
- PROMISE (1)
- PSMA-RADS (1)
- Parkinson disease (1)
- Parkinson’s disease (1)
- Positron emission tomography (1)
- Radium (1)
- SPECT (1)
- Somatostatin receptor expression (1)
- WB-DW-MRI (1)
- [18F]Fluorodeoxythymidine (1)
- [\(^{68}\)Ga] pentixafor (1)
- [\(^{68}\)Ga]Pentixafor (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{18}\)F-FDG PET/CT (1)
- \(^{68}\)Ga-Pentixafor (1)
- acute myeloid leukemia (1)
- adrenal incidentaloma (1)
- adrenocortical carcinoma (1)
- alpha-emitters (1)
- amino acids (1)
- autologous transplantation (1)
- bone-targeting radiopharmaceuticals (1)
- cancer (1)
- cardiac neurohormonal system (1)
- cells (1)
- chemokine receptor-4 (1)
- cholinergic activity (1)
- coefficient (1)
- cognitive decline (1)
- diffusion weighted MRI (1)
- dopamine acetylcholine (1)
- dosimetry (1)
- early response (1)
- endocrinology (1)
- esophagogastric junction (1)
- experience (1)
- folinic acid (1)
- follicular lymphoma (1)
- gemcitabine (1)
- glioblastoma (1)
- glioblastoma multiforme (1)
- glioma (1)
- heart failure (1)
- hyperkalemia (1)
- imaging (1)
- imaging proliferation (1)
- imaging techniques (1)
- immunostaining (1)
- in-vivo (1)
- inhibition (1)
- initial experience (1)
- irinotecan (1)
- kidney function (1)
- levodopa-induced dyskinesia (1)
- locally advanced disease (1)
- macrophages (1)
- magnetic resonance imaging (1)
- malignancies (1)
- malignant lymphoma (1)
- mammalian target of rapamycin (1)
- management (1)
- microenvironment (1)
- microglial cells (1)
- molecular medicine (1)
- nab-paclitaxel (1)
- neoadjuvant chemotherapy (1)
- neuroendocrine neoplasia (1)
- nicotinic receptors (1)
- non-Hodgkin's lymphoma (1)
- non-hodgkins-lymphoma (1)
- nuclear cardiology (1)
- nuclear medicine therapy (1)
- optimization (1)
- oxaliplatin (1)
- pancreatic cancer (1)
- phosphatidylinositol-3-kinase (1)
- pleural mesothelioma (1)
- positron emission tomography/computed tomography (1)
- prognostic value (1)
- prostate-specific membrane antigen (1)
- radionuclide therapy (1)
- radiotracer (1)
- recurrence (1)
- renal scintigraphy (1)
- reporting and data system (1)
- response evaluation (1)
- salvage radiotherapy (1)
- signaling pathway (1)
- somatostatin (1)
- somatostatin receptor (1)
- standardized reporting (1)
- stem-cell transplantation (1)
- survival (1)
- target (1)
- therapeutic target (1)
- treatment response (1)
- tumor (1)
- whole body MRI (1)
- whole-body (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (29)
- Medizinische Klinik und Poliklinik II (8)
- Pathologisches Institut (6)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für Klinische Biochemie und Pathobiochemie (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Medizinische Klinik und Poliklinik I (2)
- Neurologische Klinik und Poliklinik (2)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Medizinische Strahlenkunde und Zellforschung (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (2)
Background
Salvage radiotherapy (SRT) is clinically established in prostate cancer (PC) patients with PSA persistence or biochemical relapse (BCR) after prior radical surgery. PET/CT imaging prior to SRT may be performed to localize disease recurrence. The recently introduced \(^{68}\)Ga-PSMA outperforms other PET tracers for detection of recurrence and is therefore expected also to impact radiation planning.
Forty-five patients with PSA persistence (16 pts) or BCR (29 pts) after prior prostatectomy, scheduled to undergo SRT of the prostate bed, underwent \(^{68}\)Ga-PSMA PET/CT. The median PSA level was 0.67 ng/ml. The impact of \(^{68}\)Ga-PSMA PET/CT on the treatment decision was assessed. Patients with oligometastatic (≤5 lesions) PC underwent radiotherapy (RT), with the extent of the RT area and dose escalation being based on PET positivity.
Results
Suspicious lesions were detected in 24/45 (53.3 %) patients. In 62.5 % of patients, lesions were only detected by 68Ga-PSMA PET. Treatment was changed in 19/45 (42.2 %) patients, e.g., extending SRT to metastases (9/19), administering dose escalation in patients with morphological local recurrence (6/19), or replacing SRT by systemic therapy (2/19). 38/45 (84.4 %) followed the treatment recommendation, with data on clinical follow-up being available in 21 patients treated with SRT. All but one showed biochemical response (mean PSA decline 78 ± 19 %) within a mean follow-up of 8.12 ± 5.23 months.
Conclusions
\(^{68}\)Ga-PSMA PET/CT impacts treatment planning in more than 40 % of patients scheduled to undergo SRT. Future prospective studies are needed to confirm this significant therapeutic impact on patients prior to SRT.